Skip to main content

Advertisement

SpringerLink
Log in

Integration of Clinical Genetic Testing in Cardiovascular Care

  • Cardiovascular Genetics (D Rader, Section Editor)
  • Published:
Current Genetic Medicine Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Knowledge of genetic etiologies for inherited cardiovascular disease has expanded in recent years giving providers the potential to tailor medical management and family screening based on a patient’s genotype for some conditions. This paper highlights recent advances in Mendelian inherited cardiovascular disease such as Marfan syndrome, hypertrophic cardiomyopathy, and familial hypercholesterolemia.

Recent Findings

Genetic testing has gone through a rapid evolution thanks to technological advancements in sequencing technology. The combination of increased utility and decreased cost is lowering the barriers for testing. Development of next-generation panels and whole-exome and whole-genome sequencing allows for broader testing and, in some cases, gene discoveries. Genetics is fueling growth in pharmacogenetics and complex disease research and has even led to novel therapeutics and new indications for old therapeutics.

Summary

The integration of clinical genetic testing into patient care is becoming increasingly common as the field expands and more institutions adopt the practice. The interpretation of genetic testing results can be complicated as there are a wide range of tools to determine the pathogenicity of a DNA variant identified in a patient. The psychological impact of genetic counseling necessitates pre- and post-test genetic counseling.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Recently published papers of particular interest have been highlighted as: • Of importance •• Of major importance

  1. • Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249–54. Recent developments in detection such as genetic testing are shown to increase detection and in turn, the prevalence of hypertrophic cardiomyopathy from 1/500 to 1/200.

  2. • Gidding SS, Champagne M, de Ferranti SD, Defesche J, Ito MK, Knowles JW, McCrindle B, Raal F, Rader D, Santos RD, Lopes-Virella M, Watts GF, Wierzbicki AS. The agenda for Familial Hypercholesterolemia, a scientific statement from the American Heart Association. Circulation. 2015;132(22):2167–92. Recent comprehensive statement from the AHA regarding the diagnosis, treatment and genetic testing and cascade screening options for patients and their families.

  3. • Nakano Y, Shimogaki W. Genetics of long QT. J Hum Genet. 2016;61(1):51–55. Summarizes recent developments in Long QT genetic testing.

  4. • Milewicz D, Hostetler E, Wallace S, Mellor-Crummey L, Gong L, Pannu H, Guo DC, Regalado E. Precision medical and surgical management for thoracic aortic aneurysms and acute aortic dissections based on the causative mutant gene. J Cardiovasc Surg. 2016;57(2):172–7. Current recommendations on surgical threshold for patients with aortic aneurysms and dissections.

  5. O’Donnell CJ, Nabel E. Genomics of cardiovascular disease. New Engl J Med. 2011;365:2098–109.

    Article  PubMed  Google Scholar 

  6. The White House, O.O.T.P.S. FACT SHEET: president Obama’s precision medicine initiative. 2015.

  7. Counselors, N.S.O.G. Professional status survey: salary & benefits. 2014: www.nsgc.org.

  8. Ingles J, McGaughran J, Scuffham PA, et al. A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy. Heart. 2012;98(8):625–30.

    Article  PubMed  Google Scholar 

  9. Wonderling D, Umans-Eckenhausen M, Marks D, Defesche JC, Kastelein JJ, Thorogood M. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. Semin Vasc Med. 2004;4(1):97–104.

    Article  PubMed  Google Scholar 

  10. • Hershberger RE, Siegfried J. Update 2011: clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol. 2011;57:1641–49. Comprehensive review on familial dilated cardiomyopathy.

  11. Tester DJ, Ackerman M. Genetic testing for potentially lethal, highly treatable inherited cardiomyopathies/channelopathies in clinical practice. Circulation. 2011;123:1021–37.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Austin J, Semaka A, Hadjipavlou G. Conceptualizing genetic counseling as psychotherapy in the era of genomic medicine. J Genet Couns. 2014;23(6):903–9.

    Article  PubMed  PubMed Central  Google Scholar 

  13. van der Roest WP, Roest WP. Family letters are an effective way to inform relatives about inherited cardiac disease. Am J Med Genet. 2009;149A:357–63.

    Article  PubMed  Google Scholar 

  14. • Harrison TA, Doyle D, McGowan C, Cohen L, Repass E, Pfau RB, Brown T, Billing for medical genetics and genetic counseling services. J Genet Couns. 2010;19(1):38–43. Comprehensive gude on how to get reimbursed for genetic counseling services.

  15. Goldstein JL, Dana S, Brunschede GY, Brown MS. Genetic heterogeneity in familial hypercholesterolemia: evidence for two different mutations affecting functions of low-density lipoprotein receptor. Proc Nat Acad Sci. 1975;72(3):1092–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Sanger FC, Coulson R. A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. J Mol Biol. 1975;94:441–8.

    Article  CAS  PubMed  Google Scholar 

  17. •• Excellence N.I.f.H.a.C. Familial hypercholesterolaemia: identification and management: NICE quality standard. 2013. Guidelines developed for FH by the https://www.nice.org.uk/guidance/qs41. Accessed 22 Mach 2016. British guidelines on familial hypercholesterolemia.

  18. • Nordestgaard BG, Chapman M., Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Kees Hovingh G, Kovanen PT, Boileau C, Averna M, Borén J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjærg-Hansen A, for the European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart. 2013;34:3478–90. European guidelines for identifying and treating familial hypercholesterolemia.

  19. •• Gersh BJ, Maron B, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary. J Thor Cardiovasc Surg. 2011;142(6):1303–38. United States guidelines on diagnosing and managing hypertrophic cardiomyopathy.

  20. •• Priori Silvia G, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, Blom N, Brugada J, Chiang C-E, Huikuri H, Kannankeril P, Krahn A, Leenhardt A, Moss A, Schwartz PJ, Shimizu W, Tomaselli G, Tracy C, Ackerman M, Belhassen B, Mark Estes III NA, Fatkin D, Kalman J, Kaufman E, Kirchhof P, Schulze-Bahr E, Wolpert C, Vohra J, Refaat M, Etheridge SP, Campbell RM, Martin ET, Chye Quek S, HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2012;10(12):932–1963. HRS consensus statement on the diagnosis, treatment and management of arrhythmia syndromes.

  21. •• Hiratzka LF, Bakris GL, Beckman JA, et al. ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: executive summary. J Am Coll Cardiol. 2010;55(14):509–1544. Guidelines on diagnosing and managing patients with thoracic aortic disease.

  22. Office NE. Genetic counselling program gives Cigna customers increased access to genetic counselors. 2013.

  23. Sakai LY, Keene D, Engvall E. Fibrillin, a new 350-kD glycoprotein, is a component of extracellular microfibrils. J Cell Biol. 1986;103(6):2499–24509.

    Article  CAS  PubMed  Google Scholar 

  24. Hollister DW, Godfrey M, Sakai LY, Pyeritz RE. Immunohistologic abnormalities of the microfibrillar-fiber system in the Marfan syndrome. New Engl J Med. 1990;323(3):152–9.

    Article  CAS  PubMed  Google Scholar 

  25. Kainulainen K, Pulkkinen L, Savolainen A, Kaitila I, Peltonen L. Location on chromosome 15 of the gene defect causing Marfan syndrome. New Engl J Med. 1990;323:152–9.

    Article  Google Scholar 

  26. Dietz H, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, Puffenberger EG, Hamosh A, Nanthakumar E, Curristin S, Stetten G, Meyers DA, Francomano CA. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991;352:337–9.

    Article  CAS  PubMed  Google Scholar 

  27. Dietz H, Saraiva J, Pyeritz RE, Cutting GR, Francomano CA. Clustering of fibrillin (FBN1) missense mutations in Marfan syndrome patients at cystein residues in EGF-like domains. Hum Mutat. 1992;1:366–74.

    Article  CAS  PubMed  Google Scholar 

  28. Faivre L, Collod-Beroud G, Loeys BL, Child A, Binquet C, Gautier E, Callewaert B, Arbustini E, Mayer K, Arslan-Kirchner M, Kiotsekoglou A, Comeglio P, Marziliano N, Dietz HC, Halliday D, Beroud C, Bonithon-Kopp C, Claustres M, Muti C, Plauchu H, Robinson PN, Adès LC, Biggin A, Benetts B, Brett M, Holman KJ, De Backer J, Coucke P, Francke U, De Paepe A, Jondeau G, Boileau C. Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. Am J Hum Genet. 2007;81(3):454–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Faivre L, Collod-Beroud G, Callewaert B, Child A, Binquet C, Gautier E, et al. Clinical and mutation-type analysis from an international series of 198 probands with a pathogenic FBN1 exons 24-32 mutation. Eur J Hum Genet. 2009;17:491–501.

    Article  CAS  PubMed  Google Scholar 

  30. • Franken R, Radonic T, Micha D, Maugeri A, van Dijk FS, Meijers-Heijboer HE, Timmermans J, Scholte AJ, van den Berg MP, Groenink M, Mulder BJ, Zwinderman AH, de Waard V, Pals G. Beneficial outcome of losartan therapy depends on type of FBN1 mutation in Marfan syndrome. Circ Cardiovasc Genet. 2015;8(2):383–8. First finding that response to therapy in Marfan syndrome is based on genotype.

  31. Milewicz D, Regalado E. Use of genetics for personalized management of heritable thoracic aortic disease: how do we get there? J Thoracic Cardiovasc Surg. 2015;149(2):S3–5.

    Article  Google Scholar 

  32. Cirino AL, Carolyn Ho. Hypertrophic cardiomyopathy overview. Gene Reviews 2014; Available from: http://www.ncbi.nlm.nih.gov/books/NBK1768/.

  33. Nannenberg EA, Michels M, Christiaans I, Majoor-Krakauer D, Hoedemaekers YM, van Tintelen JP, Lombardi MP, ten Cate FJ, Schinkel AF, Tijssen JG, van Langen IM, Wilde AA, Sijbrands EJ. Mortality risk of untreated myosin-binding protein C-related hypertrophic cardiomyopathy: insight into the natural history. Am Coll Cardiol. 2011;58(23):2406–16.

    Article  CAS  Google Scholar 

  34. Valsartan for attenuating disease evolution in early sarcomeric HCM (VANISH). 2015. www.clinicaltrials.gov. Available from 22 03 2016.

  35. Brown MS, Goldstein JL. Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. Proc Natl Acad Sci USA. 1974;71(3):788–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Whitfield AJ, Barrett P, van Bockxmeer FM, Burnett JR. Lipid disorders and mutations in the APOB gene. Clin Chem. 2004;50:1725–32.

    Article  CAS  PubMed  Google Scholar 

  37. Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derré A, Villéger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154–6.

    Article  CAS  PubMed  Google Scholar 

  38. Cariou B, Ouguerram K, Zaïr Y, Guerois R, Langhi C, Kourimate S, Benoit I, Le May C, Gayet C, Belabbas K, Dufernez F, Chétiveaux M, Tarugi P, Krempf M, Benlian P, Costet P. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol. 2009;29(12):2191–7.

    Article  CAS  PubMed  Google Scholar 

  39. Hooper AJ, Marais A, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis. 2007;193(2):445–8.

    Article  CAS  PubMed  Google Scholar 

  40. Garcia K. Federal panel backs approval of new drug to fight heart attacks. Routledge: New York Times; 2015.

    Google Scholar 

  41. Garcia CK, Wilund K, Arca M, Zuliani G, Fellin R, Maioli M, Calandra S, Bertolini S, Cossu F, Grishin N, Barnes R, Cohen JC, Hobbs HH. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science. 2001;292:1394–8.

    Article  CAS  PubMed  Google Scholar 

  42. Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, Kwiterovich P, Shan B, Barnes R, Hobbs HH. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science. 2000;290:1771–5.

    Article  CAS  PubMed  Google Scholar 

  43. Fouchier S, Dallinga-Thie GM, Meijers JCM, Zelcer N, Kastelein JJP, Defesche JC, Hovingh GK. Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia. Circ Res. 2014;115(6):552–5.

    Article  CAS  PubMed  Google Scholar 

  44. Sjouke B, Kusters D, Kindt I, Besseling J, Defesche JC, Sijbrands EJ, Roeters van Lennep JE, Stalenhoef AF, Wiegman A, de Graaf J, Fouchier SW, Kastelein JJ, Hovingh GK. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart. 2015;36(9):560–5.

    Article  Google Scholar 

  45. Benn M, Watts G, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J ClinEndocrinol Metab. 2012;97(11):3956–64.

    Article  CAS  Google Scholar 

  46. Knowles JW, Youngblom E. Familial hypercholesterolemia. 2014. http://www.ncbi.nlm.nih.gov/books/NBK174884/. Accessed 21 March 2016.

  47. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, Witteman JC, Lansberg PJ, Kastelein JJ, Sijbrands EJ. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. Br Med J. 2008;337:a2423.

    Article  Google Scholar 

  48. Hopkins P. Defining the challenges of familial hypercholesterolemia screening: introduction. J Clin Lipidol. 2010;4:342–5.

    Article  PubMed  Google Scholar 

  49. Mataa P, Alonsob R, Pérez-Jiménezc F. Screening for familial hypercholesterolemia: a model for preventive medicine. Rev Espanola Cardiol. 2014;67(9):685–8.

    Article  Google Scholar 

  50. Ademi Z, Watts G, Pang J, Sijbrands EJ, van Bockxmeer FM, O’Leary P, Geelhoed E, Liew D. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. J Clin Lipidol. 2014;8(4):390–400.

    Article  PubMed  Google Scholar 

  51. Rader D. Specialist perspective on FH risk and care continuum: stopping the progression from genetic mutation to vascular disease. In: FH 2014 Global Summit. 2014.

  52. Consortium, I.H.G.S. Finishing the euchromatic sequence of the human genome. Nature. 2004;431:931–45.

    Article  Google Scholar 

  53. • Gahl W, Wise AL, Ashely EA. The undiagnosed diseases network of the national institute of health. J Am Med Assoc. 2015;314(17):1797–98. Update on the current launch of the Undiagnosed Disease Program which is accepting applications from all physicians.

  54. Gahl WA, Markello T, Toro C, Fajardo KF, Sincan M, Gill F, Carlson-Donohoe H, Gropman A, Pierson TM, Golas G, Wolfe L, Groden C, Godfrey R, Nehrebecky M, Wahl C, Landis DM, Yang S, Madeo A, Mullikin JC, Boerkoel CF, Tifft CJ, Adams D. The national institutes of health undiagnosed diseases program: insights into rare diseases. Genet Med. 2012;14(1):51–9.

    Article  CAS  PubMed  Google Scholar 

  55. Priest J, Scott R, Ceresnak MD, Frederick E, Dewey MD. Molecular diagnosis of long QT syndrome at 10 days of life by rapid whole genome sequencing. Heart Rhythm. 2014;11(10):1707–13.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Rettie AE, Korzekwa K, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, Trager WF. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Chem Res Toxicol. 1994;5(1):54–9.

    Article  Google Scholar 

  57. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Müller CR, Strom TM, Oldenburg J. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004;427(6974):537–41.

    Article  CAS  PubMed  Google Scholar 

  58. Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008;111:4106–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Voora D, Shah S, Reed CR, Zhai J, Crosslin DR, Messer C, Salisbury BA, Ginsburg GS. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circ Cardiovasc Genet. 2008;1:100–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Ramsey LB, Johnson S, Caudle KE, Haidar CE, Voora D, Wilke RA, Maxwell WD, McLeod HL, Krauss RM, Roden DM, Feng Q, Cooper-DeHoff RM, Gong L, Klein TE, Wadelius M, Niemi M. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther. 2014;96(4):423–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Global Lipids Genetics Consortium, Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, Ganna A, Chen J, Buchkovich ML, Mora S, Beckmann JS, Bragg-Gresham JL, Chang HY, Demirkan A, Den Hertog HM, Do R, Donnelly LA, Ehret GB, Esko T, Feitosa MF, Ferreira T, Fischer K, Fontanillas P, Fraser RM, Freitag DF, Gurdasani D, Heikkilä K, Hyppönen E, Isaacs A, Jackson AU, Johansson A, Johnson T, Kaakinen M, Kettunen J, Kleber ME, Li X, Luan J, Lyytikäinen LP, Magnusson PK, Mangino M, Mihailov E, Montasser ME, Müller-Nurasyid M, Nolte IM, O’Connell JR, Palmer CE, Perola M, Petersen AK, Sanna S, Saxena R, Service SK, Shah S, Shungin D, Sidore C, Song C, Strawbridg RJ, Surakka I, Tanaka T, Teslovich TM, Thorleifsson G, Van den Herik EG, Voight BF, Volcik KA, Waite LL, Wong A, Wu Y, Zhang W, Absher D, Asiki G, Barroso I, Been LF, Bolton JL, Bonnycastle LL, Brambilla P, Burnett MS, Cesana G, Dimitriou M, Doney AS, Döring A, Elliott P, Epstein SE, Eyjolfsson GI, Gigante B, Goodarzi MO, Grallert H, Gravito ML, Groves CJ, Hallmans G, Hartikainen AL, Hayward C, Hernandez D, Hicks AA, Holm H, Hung YJ, Illig T, Jones MR, Kaleebu P, Kastelein JJ, Khaw KT, Kim E, Klopp N, Komulainen P, Kumari M, Langenberg C, Lehtimäki T, Lin SY, Lindström J, Loos RJ, Mach F, McArdle WL, Meisinger C, Mitchell BD, Müller G, Nagaraja R, Narisu N, Nieminen TV, Nsubuga RN, Olafsson I, Ong KK, Palotie A, Papamarkou T, Pomilla C, Pouta A, Rader DJ, Reilly MP, Ridker PM, Rivadeneira F, Rudan I, Ruokonen A, Samani N, Scharnagl H, Seeley J, Silander K, Stancáková A, Stirrups K, Swift AJ, Tiret L, Uitterlinden AG, van Pelt LJ, Vedantam S, Wainwright N, Wijmenga C, Wild SH, Willemsen G, Wilsgaard T, Wilson JF, Young EH, Zhao JH, Adair LS, Arveiler D, Assimes TL, Bandinelli S, Bennett F, Bochud M, Boehm BO, Boomsma DI, Borecki IB, Bornstein SR, Bovet P, Burnier M, Campbell H, Chakravarti A, Chambers JC, Chen YD, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Feranil AB, Ferrières J, Ferrucci L, Freimer NB, Gieger C, Groop LC, Gudnason V, Gyllensten U, Hamsten A, Harris TB, Hingorani A, Hirschhorn JN, Hofman A, Hovingh GK, Hsiung CA, Humphries SE, Hunt SC, Hveem K, Iribarren C, Järvelin MR, Jula A, Kähönen M, Kaprio J, Kesäniemi A, Kivimaki M, Kooner JS, Koudstaal PJ, Krauss RM, Kuh D, Kuusisto J, Kyvik KO, Laakso M, Lakka TA, Lind L, Lindgren CM, Martin NG, März W, McCarthy MI, McKenzie CA, Meneton P, Metspalu A, Moilanen L, Morris AD, Munroe PB, Njølstad I, Pedersen NL, Power C, Pramstaller PP, Price JF, Psaty BM, Quertermous T, Rauramaa R, Saleheen D, Salomaa V, Sanghera DK, Saramies J, Schwarz PE, Sheu WH, Shuldiner AR, Siegbahn A, Spector TD, Stefansson K, Strachan DP, Tayo BO, Tremoli E, Tuomilehto J, Uusitupa M, van Duijn CM, Vollenweider P, Wallentin L, Wareham NJ, Whitfield JB, Wolffenbuttel BH, Ordovas JM, Boerwinkle E, Palmer CN, Thorsteinsdottir U, Chasman DI, Rotter JI, Franks PW, Ripatti S, Cupples LA, Sandhu MS, Rich SS, Boehnke M, Deloukas P, Kathiresan S, Mohlke KL, Ingelsson E, Abecasis GR. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45(11):1274–83.

    Article  Google Scholar 

  62. Parmar PG, Taal H, Timpson NJ, Thiering E, Lehtimäki T, Marinelli M, Lind PA, Howe LD, Verwoert G, Aalto V, Uitterlinden AG, Briollais L, Evans DM, Wright MJ, Newnham JP, Whitfield JB, Lyytikäinen LP, Rivadeneira F, Boomsma DI, Viikari J, Gillman MW, Stpourcain B, Hottenga JJ, Montgomery GW, Hofman A, Kähönen M, Martin NG, Tobin MD, Raitakari O, Vioque J, Jaddoe VW, Jarvelin MR, Beilin LJ, Heinrich J, van Duijn CM, Pennell CE, EArly genetics and lifecourse epidemiology consortium, Lawlor DA, Palmer LJ. International GWAS Consortium identifies novel loci associated with blood pressure in children and adolescents. Circ Cardiovasc Genet. 2016;9:807–18.

    Article  Google Scholar 

  63. Morris AP, Voight B, Teslovich TM, Ferreira T, Segrè AV, Steinthorsdottir V, Strawbridge RJ, Khan H, Grallert H, Mahajan A, Prokopenko I, Kang HM, Dina C, Esko T, Fraser RM, Kanoni S, Kumar A, Lagou V, Langenberg C, Luan J, Lindgren CM, Müller-Nurasyid M, Pechlivanis S, Rayner NW, Scott LJ, Wiltshire S, Yengo L, Kinnunen L, Rossin EJ, Raychaudhuri S, Johnson AD, Dimas AS, Loos RJ, Vedantam S, Chen H, Florez JC, Fox C, Liu CT, Rybin D, Couper DJ, Kao WH, Li M, Cornelis MC, Kraft P, Sun Q, van Dam RM, Stringham HM, Chines PS, Fischer K, Fontanillas P, Holmen OL, Hunt SE, Jackson AU, Kong A, Lawrence R, Meyer J, Perry JR, Platou CG, Potter S, Rehnberg E, Robertson N, Sivapalaratnam S, Stancáková A, Stirrups K, Thorleifsson G, Tikkanen E, Wood AR, Almgren P, Atalay M, Benediktsson R, Bonnycastle LL, Burtt N, Carey J, Charpentier G, Crenshaw AT, Doney AS, Dorkhan M, Edkins S, Emilsson V, Eury E, Forsen T, Gertow K, Gigante B, Grant GB, Groves CJ, Guiducci C, Herder C, Hreidarsson AB, Hui J, James A, Jonsson A, Rathmann W, Klopp N, Kravic J, Krjutskov K, Langford C, Leander K, Lindholm E, Lobbens S, Männistö S, Mirza G, Mühleisen TW, Musk B, Parkin M, Rallidis L, Saramies J, Sennblad B, Shah S, Sigurðsson G, Silveira A, Steinbach G, Thorand B, Trakalo J, Veglia F, Wennauer R, Winckler W, Zabaneh D, Campbell H, van Duijn C, Uitterlinden AG, Hofman A, Sijbrands E, Abecasis GR, Owen KR, Zeggini E, Trip MD, Forouhi NG, Syvänen AC, Eriksson JG, Peltonen L, Nöthen MM, Balkau B, Palmer CN, Lyssenko V, Tuomi T, Isomaa B, Hunter DJ, Qi L, Wellcome Trust Case Control Consortium, Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) Investigators, Genetic Investigation of ANthropometric Traits (GIANT) Consortium, Asian Genetic Epidemiology Network-Type 2 Diabetes (AGEN-T2D) Consortium, South Asian Type 2 Diabetes (SAT2D) Consortium, Shuldiner AR, Roden M, Barroso I, Wilsgaard T, Beilby J, Hovingh K, Price JF, Wilson JF, Rauramaa R, Lakka TA, Lind L, Dedoussis G, Njølstad I, Pedersen NL, Khaw KT, Wareham NJ, Keinanen-Kiukaanniemi SM, Saaristo TE, Korpi-Hyövälti E, Saltevo J, Laakso M, Kuusisto J, Metspalu A, Collins FS, Mohlke KL, Bergman RN, Tuomilehto J, Boehm BO, Gieger C, Hveem K, Cauchi S, Froguel P, Baldassarre D, Tremoli E, Humphries SE, Saleheen D, Danesh J, Ingelsson E, Ripatti S, Salomaa V, Erbel R, Jöckel KH, Moebus S, Peters A, Illig T, de Faire U, Hamsten A, Morris AD, Donnelly PJ, Frayling TM, Hattersley AT, Boerwinkle E, Melander O, Kathiresan S, Nilsson PM, Deloukas P, Thorsteinsdottir U, Groop LC, Stefansson K, Hu F, Pankow JS, Dupuis J, Meigs JB, Altshuler D, Boehnke M, McCarthy MI, DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet. 2012;44(9):981–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, Saleheen D, Kyriakou T, Nelson CP, Hopewell JC, Webb TR, Zeng L, Dehghan A, Alver M, Armasu SM, Auro K, Bjonnes A, Chasman DI, Chen S, Ford I, Franceschini N, Gieger C, Grace C, Gustafsson S, Huang J, Hwang SJ, Kim YK, Kleber ME, Lau KW, Lu X, Lu Y, Lyytikäinen LP, Mihailov E, Morrison AC, Pervjakova N, Qu L, Rose LM, Salfati E, Saxena R, Scholz M, Smith AV, Tikkanen E, Uitterlinden A, Yang X, Zhang W, Zhao W, de Andrade M, de Vries PS, van Zuydam NR, Anand SS, Bertram L, Beutner F, Dedoussis G, Frossard P, Gauguier D, Goodall AH, Gottesman O, Haber M, Han BG, Huang J, Jalilzadeh S, Kessler T, König IR, Lannfelt L, Lieb W, Lind L, Lindgren CM, Lokki ML, Magnusson PK, Mallick NH, Mehra N, Meitinger T, Memon FU, Morris AP, Nieminen MS, Pedersen NL, Peters A, Rallidis LS, Rasheed A, Samuel M, Shah SH, Sinisalo J, Stirrups KE, Trompet S, Wang L, Zaman KS, Ardissino D, Boerwinkle E, Borecki IB, Bottinger EP, Buring JE, Chambers JC, Collins R, Cupples LA, Danesh J, Demuth I, Elosua R, Epstein SE, Esko T, Feitosa MF, Franco OH, Franzosi MG, Granger CB, Gu D, Gudnason V, Hall AS, Hamsten A, Harris TB, Hazen SL, Hengstenberg C, Hofman A, Ingelsson E, Iribarren C, Jukema JW, Karhunen PJ, Kim BJ, Kooner JS, Kullo IJ, Lehtimäki T, Loos RJ, Melander O, Metspalu A, März W, Palmer CN, Perola M, Quertermous T, Rader DJ, Ridker PM, Ripatti S, Roberts R, Salomaa V, Sanghera DK, Schwartz SM, Seedorf U, Stewart AF, Stott DJ, Thiery J, Zalloua PA, O’Donnell CJ, Reilly MP, Assimes TL, Thompson JR, Erdmann J, Clarke R, Watkins H, Kathiresan S, McPherson R, Deloukas P, Schunkert H, Samani NJ, Farrall M, CARDIoGRAMplusC4D Consortium. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet. 2015;47(10):1121–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Ripatti S, Tikkanen E, Orho-Melander M, Havulinna AS, Silander K, Sharma A, Guiducci C, Perola M, Jula A, Sinisalo J, Lokki ML, Nieminen MS, Melander O, Salomaa V, Peltonen L, Kathiresan S. A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet. 2010;376(9750):1393–400.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Goldstein BA, Knowles JW, Salfati E, Ioannidis JP, Assimes TL. Simple, standardized incorporation of genetic risk into non-genetic risk prediction tools for complex traits: coronary heart disease as an example. Front Genet. 2014;1(5):254.

    Google Scholar 

  67. Knowles J, Pavlovic A, McConnell MV, Ashley EA. A randomized trial of personal genomics for preventive cardiology: design and challenges. Circ Cardiovasc Genet. 2012;5(3):368–76.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Umans-Eckenhausen MA, Defesche J, van Dam MJ, Kastelein JJ. Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia. Arch Int Med. 2003;163(1):65–8.

    Article  Google Scholar 

  69. Bai R, Napolitano C, Bloise R, Monteforte N, Priori SG. Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing. Circulation. 2009;2(1):6–15.

    CAS  PubMed  Google Scholar 

  70. Havndrup O, Bundgaard H, Andersen PS, Larsen LA, Vuust J, Kjeldsen K, Christiansen M. Outcome of clinical versus genetic family screening in hypertrophic cardiomyopathy with focus on cardiac beta-myosin gene mutations. Cardiovasc Res. 2003;57(2):347–57.

    Article  CAS  PubMed  Google Scholar 

  71. Directors, A.B.O. ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing. Genet Med. 2015;17(1):68–9.

    Article  Google Scholar 

  72. Yang Y, Muzny MD, Xia F, Niu Z, Person R, Ding Y, Ward P, Braxton A, Wang M, Buhay C, Veeraraghavan N, Hawes A, Chiang T, Leduc M, Beuten J, Zhang J, He W, Scull J, Willis A, Landsverk M, Craigen WJ, Bekheirnia MR, Stray-Pedersen A, Liu P, Wen S, Alcaraz W, Cui H, Walkiewicz M, Reid J, Bainbridge M, Patel A, Boerwinkle E, Beaudet AL, Lupski JR, Plon SE, Gibbs RA, Eng CM. Molecular findings among patients referred for clinical whole-exome sequencing. J Am Med Assoc. 2014;312(18):1870–9.

    Article  CAS  Google Scholar 

  73. Aronson SJ, Clark EH, Varugheese M, Baxter S, Babb LJ, Rehm HL. Communicating new knowledge on previously reported genetic variants. Genet Med. 2012;14(8):713–9.

    Article  PubMed Central  Google Scholar 

  74. Pariani MJ. Lessons learned from a re-review of FBN1 variants utilizing new tools in variant review. In: American college of medical genetics. Tampa: University of South Florida; 2016.

  75. Pepin MG, Murray M, Bailey S, Leistritz-Kessler D, Schwarze U, Byers PH. The challenge of comprehensive and consistent sequence variant interpretation between clinical laboratories. Genet Med. 2016;18(1):20–4.

    Article  PubMed  Google Scholar 

  76. • Rehm HL, Berg J, Brooks LD, Bustamante CD, Evans JP, Landrum MJ, Ledbetter DH, Maglott DR, Martin CL, Nussbaum RL, Plon SE, Ramos EM, Sherry ST, Watson MS. ClinGen, ClinGen—the clinical genome resource. New Engl J Med. 2015; 372(23): 2235–42. Update on the ClinGen project which is a public data sharing effort aid in interpretation of DNA variants.

  77. Sun Y, Ruivenkamp C, Hoffer MJV, Vrijenhoek T, Kriek M, van Asperen CJ, den Dunnen JT, Santen GW. Next-generation diagnostics: gene panel, exome, or whole genome? Hum Mutat. 2015;36(6):648–55.

    Article  CAS  PubMed  Google Scholar 

  78. Hudson KL, Holohan MK, Collins FS. Keeping pace with the times—the Genetic Information Nondiscrimination Act of 2008. New Engl J Med. 2008;358(25):2661–3.

    Article  CAS  PubMed  Google Scholar 

  79. Van Driest SL, Ommen SR, Tajik AJ, Jamil Gersh BJ, Ackerman MJ. Yield of genetic testing in hypertrophic cardiomyopathy. Mayo Clin Proc. 2005;80(6):739–44.

    Article  PubMed  Google Scholar 

  80. Codd MB, Sugrue DD, Gersh BJ, Melton LJ 3rd. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy: a population-based study in Olmsted County, Minnesota, 1975–1984. Circulation. 1989;80:564–72.

    Article  CAS  PubMed  Google Scholar 

  81. Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013;10:531–47.

    Article  CAS  PubMed  Google Scholar 

  82. Morales A, Hershberger R. Genetic evaluation of dilated cardiomyopathy. Curr Cardiol Rep. 2013;15(7):1–8.

    Article  Google Scholar 

  83. Callis TE, Jensen BC, Weck KE, Willis MS. Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all. Expert Rev Mol Diagn. 2010;10(3):329–51.

    Article  CAS  PubMed  Google Scholar 

  84. Peters S. Advances in the diagnostic management of arrhythmogenic right ventricular dysplasia–cardiomyopathy. Int J Cardiol. 2006;113(1):4–11.

    Article  PubMed  Google Scholar 

  85. Sen-Chowdhry S, Syrris P, McKenna WJ. Role of genetic analysis in the management of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2007;50(19):1813–21.

    Article  CAS  PubMed  Google Scholar 

  86. Schwartz PJ, Stramba-Badiale M, Crotti L, Pedrazzini M, Besana A, Bosi G, Gabbarini F, Goulene K, Insolia R, Mannarino S, Mosca F, Nespoli L, Rimini A, Rosati E, Salice P, Spazzolini C. Prevalence of the congenital long-QT syndrome. Circulation. 2009;120(18):1761–9.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Napolitano C, Priori SG, Schwartz PJ, Bloise R, Ronchetti E, Nastoli J, Bottelli G, Cerrone M, Leonardi S. Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. J Am Med Assoc. 2005;294(23):2975–80.

    Article  CAS  Google Scholar 

  88. Patel SS, Anees SS, Ferrick KJ. Prevalence of a Brugada pattern electrocardiogram in an urban population in the United States. Pacing Clin Electrophysiol. 2009;32(6):704–8.

    Article  PubMed  Google Scholar 

  89. Hedley PL, Jørgensen P, Schlamowitz S, Moolman-Smook J, Kanters JK, Corfield VA, Christiansen M. The genetic basis of Brugada syndrome: a mutation update. Hum Mut. 2009;30(9):1256–66.

    Article  CAS  PubMed  Google Scholar 

  90. Albornoz G, Coady MA, Roberts M, Davies RR, Tranquilli M, Rizzo JA, John A. Elefteriades, Familial thoracic aortic aneurysms and dissections—incidence, modes of inheritance, and phenotypic patterns. Ann Thoracic Surg. 2006;82(4):1405–6.

    Article  Google Scholar 

  91. Dong SB, Zheng J, Ma WG, Chen MJ, Cheng LJ, He L, Xing QH, Sun LZ. Identification and surgical repair of familial thoracic aortic aneurysm and dissection caused by TGFBR1 mutation. Annal Vasc Surg. 2014;28(8):1909–12.

    Article  Google Scholar 

  92. Rimoin D, Pyeritz RE, Korf B. Marfan syndrome and related disorders. In: Rimoin D, Pyeritz RE, Korf B, editors. Principles and practice of medical genetics. New York: Elsevier; 2013.

    Google Scholar 

  93. Loeys B, Backer JD, Van Acker P, Wettinck K, Pals G, Nuytinck L, Coucke P, De Paepe A. Comprehensive molecular screening of the FBN1 gene favors locus homogeneity of classical Marfan syndrome. Hum Mut. 2004;24(2):140–6.

    Article  CAS  PubMed  Google Scholar 

  94. Do R, Stitzie NO, Won HH, Jørgensen AB, Duga S, Angelica Merlini P, Kiezun A, Farrall M, Goel A, Zuk O, Guella I, Asselta R, Lange LA, Peloso GM, Auer PL, NHLBI Exome Sequencing Project, Girelli D, Martinelli N, Farlow DN, DePristo MA, Roberts R, Stewart AF, Saleheen D, Danesh J, Epstein SE, Sivapalaratnam S, Hovingh GK, Kastelein JJ, Samani NJ, Schunkert H, Erdmann J, Shah SH, Kraus WE, Davies R, Nikpay M, Johansen CT, Wang J, Hegele RA, Hechter E, Marz W, Kleber ME, Huang J, Johnson AD, Li M, Burke GL, Gross M, Liu Y, Assimes TL, Heiss G, Lange EM, Folsom AR, Taylor HA, Olivieri O, Hamsten A, Clarke R, Reilly DF, Yin W, Rivas MA, Donnelly P, Rossouw JE, Psaty BM, Herrington DM, Wilson JG, Rich SS, Bamshad MJ, Tracy RP, Cupples LA, Rader DJ, Reilly MP, Spertus JA, Cresci S, Hartiala J, Tang WH, Hazen SL, Allayee H, Reiner AP, Carlson CS, Kooperberg C, Jackson RD, Boerwinkle E, Lander ES, Schwartz SM, Siscovick DS, McPherson R, Tybjaerg-Hansen A, Abecasis GR, Watkins H, Nickerson DA, Ardissino D, Sunyaev SR, O’Donnell CJ, Altshuler D, Gabriel S, Kathiresan S. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature. 2015;518(7537):102–6.

    Article  CAS  PubMed  Google Scholar 

  95. DeMott K, Nherera L, Shaw EJ, Minhas R, Humphries SE, Kathoria M, Ritchie G, Nunes V, Davies D, Lee P, McDowell I, Neil A, Qureshi N, Rowlands P, Seed M, Stracey H, Thorogood M, Watson M. Clinical guidelines and evidence review for familial hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners; 2008.

    Google Scholar 

  96. Retterer K, Juusola J, Cho MT, Vitazka P, Millan F, Gibellini F, Vertino-Bell A, Smaoui N, Neidich J, Monaghan KG, McKnight D, Bai R, Suchy S, Friedman B, Tahiliani J, Pineda-Alvarez D, Richard G, Brandt T, Haverfield E, Chung WK, Bale S. Clinical application of whole-exome sequencing across clinical indications. Genet Med. 2015;369:1–9.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stanford Center for Inherited Cardiovascular Disease, Stanford Hospital, 300 Pasteur Dr, Stanford, CA, 94305, USA

    Mitchel J. Pariani

  2. Division of Cardiovascular Medicine and Cardiovascular Institute, Falk Cardiovascular Research Center, Stanford University, 870 Quarry Road, Stanford, CA, 94304, USA

    Joshua W. Knowles

Authors
  1. Mitchel J. Pariani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joshua W. Knowles
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mitchel J. Pariani.

Ethics declarations

Disclosure

Mitchel J. Pariani and Joshua W. Knowles declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Cardiovascular Genetics.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pariani, M.J., Knowles, J.W. Integration of Clinical Genetic Testing in Cardiovascular Care. Curr Genet Med Rep 4, 107–118 (2016). https://doi.org/10.1007/s40142-016-0094-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40142-016-0094-1

Keywords

Search

Navigation